Human medicines European public assessment report (EPAR): Thalidomide Celgene (previously Thalidomide Pharmion), thalidomide, Multiple Myeloma, Date of authorisation: 16/04/2008, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-399657 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Revision: 31, Status: Authorised

Case Medical Research ◽

10.31525/cmr-39964f ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Hepatitis B ◽

Cell Lymphoma ◽

Interferon Alfa ◽

Hairy Cell ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Lenalidomide Accord, lenalidomide, Multiple Myeloma, Date of authorisation: 20/09/2018, Revision: 1, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1039acf ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Revision: 31, Status: Authorised

Case Medical Research ◽

10.31525/cmr-fcd076 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Hepatitis B ◽

Cell Lymphoma ◽

Interferon Alfa ◽

Hairy Cell ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Mozobil, plerixafor, Multiple Myeloma,Hematopoietic Stem Cell Transplantation,Lymphoma, Date of authorisation: 30/07/2009, Revision: 17, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5871bb ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Hematopoietic Stem ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Farydak, panobinostat, Multiple Myeloma, Date of authorisation: 28/08/2015, Revision: 6, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1469a33 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Lenalidomide Accord, lenalidomide, Multiple Myeloma, Date of authorisation: 20/09/2018, Revision: 1, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1033e2a ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 7, Status: Authorised

Case Medical Research ◽

10.31525/cmr-b969bb ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Velcade, bortezomib, Multiple Myeloma, Date of authorisation: 26/04/2004, Revision: 41, Status: Authorised

Case Medical Research ◽

10.31525/cmr-6ac71c ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Sarcoma, Kaposi,Multiple Myeloma,Ovarian Neoplasms,Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 30, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5871c9 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Breast Neoplasms ◽

Ovarian Neoplasms ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text